Business Wire

IQM's Q-Exa Consortium Selected to Integrate German Quantum Computer Into HPC Supercomputer for the First Time

15.11.2021 20:44:00 EET | Business Wire | Press release

Share

IQM Quantum Computers has been selected to provide a quantum computing system that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. The delivery is part of a €45.3 million consortium project. The project is funded by the German Federal Ministry of Education and Research (BMBF) with €40.1 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115006110/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Picture: Federal Minister Anja Karliczek hands over the grant certificate to Jan Goetz, CEO of IQM Picture credit: BMBF/Hans-Joachim Rickel

The highly interdisciplinary consortium with experts from quantum physics and computer science, from research centers and industry, will integrate a quantum computing system provided by IQM into an HPC environment via a research purchase. This will be the first time that a gate-based quantum system will be coupled with an HPC system, making quantum acceleration of HPC applications a reality.

Quantum computers have significant potential for solving a certain class of scientific and industrial problems that cannot be addressed by classical supercomputers. To meet this challenge, HPC centers around the world are looking for ways to integrate quantum accelerators into their computing infrastructure. The ability to provide on-site solutions for quantum computing in conjunction with supercomputers is essential for the development of cutting-edge high-tech solutions from Europe. The main goal of the Q-Exa project is to establish such solutions and thus strengthen the application- related use of quantum technologies from Germany.

IQM will work with Leibniz Supercomputing Centre, LRZ - one of Germany's three national supercomputing centers, Europe's leading HPC and quantum system provider (Atos) and one of Germany's leading innovators of quantum computing applications (HQS) on this project.

Q-Exa's collaborative approach creates strong synergies with other research projects in the German and European ecosystem. The previously announced BMBF project DAQC benefits from novel simulators and fits seamlessly into the concept of the Q-Exa Co-Design Lab. The new Co-Design lab will accelerate the path to self-sustaining quantum computing, the so-called quantum advantage, through industry partnerships. This approach is in line with other German industry efforts, such as the recently formed QUTAC consortium. On the application side, research consortia such as the BMBF projects QLindA, MANIQU and other initiatives support development as industrial use cases can be tested on the Q-Exa demonstrators. Finally, the Q-Exa project supports the European strategy based on integrating quantum computing accelerators into European HPC centers. With Q-Exa, Germany can make an active contribution to these European efforts.

Federal Research Minister Anja Karliczek says: "The international race in the field of quantum technologies is in full swing. Germany and the European Union must do their utmost to keep pace in order to guarantee our technological sovereignty. We want to be able to autonomously use the technology and develop it further. The Q-Exa project opens a new promising chapter on our path to a quantum computer 'made in Germany'. Integrating a quantum computer with the infrastructure of the Leibniz Supercomputing Centre harbours enormous potential for science and industry. The project will contribute to bringing quantum computers close to practice and to provide specific application scenarios for users in science and industry. I am delighted that by launching the project we have reached the first milestone on the way towards a competitive quantum computer 'made in Germany'."

Dr. Jan Goetz, CEO of IQM Quantum Computers remarks: "We are pleased to deliver a quantum computing system to LRZ and to work with the consortium partners to integrate this system into a production-grade HPC environment. I am grateful to the Federal Ministry of Education and Research in Germany, which has given us the necessary trust and support for this ambitious project. Together we will work hard to make European technology competitive and develop the most promising hardware solutions for quantum computing here in Germany".

Prof. Dr. Dieter Kranzlmuller, Chairman of the Board of Directors, LRZ, points out: “The Q-Exa project is key for our activities within the LRZ Quantum Integration Centre (QIC) and the Munich Quantum Valley (MQV). Working with this extremely competitive consortium, we will be able to set European standards that are competitive on a global scale. Ultimately, this will be for the benefit of society as the integration of quantum computing into supercomputers, in particular on the exascale level, will speed up and open vast new research possibilities. It will bring quantum computing to users – both in academia and in industry. And now is exactly the right time to realize this in a data center environment”.

“Technological sovereignty in strategic areas like quantum computing is critical for Europe. With our Quantum Learning Machine (QLM) and strong startup partners like IQM, Atos is proud to contribute to this joint effort. It is time to build the first German quantum computer, connected to an HPC datacenter through our QLM”, says Udo Littke, Head of Atos Central Europe.

„Quantum computers will accelerate scientific progress and the development of new technologies in many areas. Chemistry, physics and biology can potentially profit from the ability to perform improved quantum mechanical simulations. Therefore, it is the next logical step to integrate quantum computers into high performance computer centers like the LRZ. We are looking very much forward to connect the end users of the LRZ with the necessary software tools to make full use of the coming computational capabilities”, says Dr. Michael Marthaler, CEO HQS Quantum Simulations GmbH.

About IQM Quantum Computers:

IQM is the Pan-European category leader in building quantum computers.

IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to develop application-specific quantum processors by the German Ministry of Education and Research in February 2021.

IQM has raised €71 million from private and public funding and has offices in Munich, Germany; Espoo, Finland; and Bilbao, Spain.

For more information, visit www.meetiqm.com.

IQM: Facts and Figures

  • Number of employees currently (November 2021): 130+ employees
  • Funding: Over € 71 Million from private and public funding
  • Founding Year: 2018

Founders:

  • Dr. Jan Goetz, CEO, Co-founder of IQM
  • Dr. Kuan Yen Tan, CTO, Co-founder of IQM
  • Prof. Mikko Mottonen, Chief scientist, Co-founder of IQM
  • Dr. Juha Vartiainen, COO, Co-founder of IQM

For more information, visit www.meetiqm.com.

Registered offices:

IQM Finland Oy Keilaranta 19
02150 Espoo Finland

IQM Germany GmbH Nymphenburgerstr. 86 80636 Munchen Germany

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Raghunath Koduvayur, Head of Marketing and Communications
Raghunath@meetiqm.com, +358504876509

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye